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Dear Editor,
Oral care using a chlorhexidine solution is commonly 
used as an infection prevention measure in European 
ICUs [1]. The preventive effects of different decontami-
nation strategies, one of which is mouthwash with chlo-
rhexidine digluconate 2  % (CHX 2  %), on the incidence 
of ICU-acquired bacteremia with multidrug-resistant 
bacteria is being investigated in a multicenter cluster-
randomized study in 13 ICUs in six European countries 
[www.clinicaltrials.gov NCT02208154] (see Supplemen-
tary Material for detailed methods). An unexpected high 
incidence of oral mucosal lesions was observed in ICU 
patients receiving CHX 2 %.
Oral mucosal lesions, including erosive lesions, ulcer-
ations, white/yellow plaque formation, and bleeding 
mucosa were observed in 29 of 295 patients (9.8 %) that 
had received CHX 2  % in the first two hospitals testing 
this intervention (Supplementary Table S1, Pictures 1–4). 
The median time to onset of oral lesions was 8.0  days 
(IQR 4.5–11.0) in the 24 patients in whom duration of 
exposure could be ascertained. CHX 2 % was discontin-
ued prematurely in 16/29 cases and oral mucosal lesions 
disappeared after cessation of CHX 2 % in all patients.
Patient characteristics were comparable for the baseline 
(n = 310) and CHX 2 % periods (n = 295; Supplementary 
Table  S2) for the two ICUs. During the baseline period 
CHX 0.20 and 0.12  % were used for oral care in hospi-
tals A and B, respectively, without evidence of oral lesions 
in any patient. All other procedures related to oral care 
remained identical in each hospital during both periods.
Amongst the CHX 2 % treated patients, occurrence of 
side effects was associated with male gender, APACHE II 
score, length of stay in the ICU, and duration of mechani-
cal ventilation, suggesting a dose-response relationship, 
with increasing risks of oral mucosal lesions for the more 
severely ill patients, undergoing mechanical ventilation, 
and receiving CHX 2 % for longer periods (Table 1). This 
hypothesis is supported by the localization of the lesions 
in the oral cavity; most lesions occurred where stasis of 
the mouthwash might have occurred—despite suction-
ing after administration—such as below the tongue and 
in the buccal pockets.
Mechanical stress during application of CHX 2 % may 
have played a role in hospital  A, where the solution 
was initially applied using Kocher’s forceps with gauzes 
and where the incidence seemed to have reduced after 
changing to application using a syringe. Hospital B had 
applied CHX 2 % with a gauze wrapped around a gloved 
finger.
In 12 patients symptoms predominantly consisted of 
pronounced white plaques at the tongue and other locali-
zations in the mouth, in some resembling Candida infec-
tion (Supplementary Picture  3). Yet, the incidence rate 
ratio between prior respiratory tract colonization with 
Candida spp. (monitored twice weekly as part of the 
study protocol and in clinical cultures) and the occur-
rence of side effects was 0.94 (95  % confidence interval 
0.09–1.79, Supplementary Table S3). An association with 
herpes reactivation could not be determined as reactiva-
tion was investigated in five affected patients only (Sup-
plementary Table S1).
The study safety committee recommended to replace 
CHX 2  % mouthwash by a CHX 1  % oral gel in the 
remaining hospitals. Since then CHX 1 % was withdrawn 
for reasons of intolerance in 2 of 419 (0.5 %) patients in 
four hospitals, after 12 and 30 days of use.
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On the basis of these findings, we recommend against 
the use of 2 % chlorhexidine digluconate mouthwash in 
ICU patients.
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Table 1 Baseline characteristics of CHX 2 % treated patients with and without adverse events
SD standard deviation, IQR interquartile range, LOS length of stay, LN log-transformed variable, MV mechanical ventilation, N number of patients
Adverse events (N = 29) No adverse events (N = 266) Pearson Chi square/indep. t test
Male gender 23 (79.3 %) 161 (60.5 %) P = 0.047
Admission type P = 0.155
Medical 13 (44.8 %) 153 (57.5 %)
Trauma 5 (17.2 %) 20 (7.5 %)
Surgical 11 (37.9 %) 93 (35.0 %)
Acute illness (y/n) 24 (82.8 %) 198 (74.4 %) P = 0.324
Antibiotic at ICU admission (y/n) 11/29 (37.9 %) 123/259 (47.5 %) P = 0.328
Age, mean (SD) 60.4 (13.3) 60.1 (15.7) P = 0.921
APACHE II, mean (SD) 26.7 (8.0) 19.6 (8.6) P < 0.0005
ICU‑LOS, median (IQR) 28 (21–41.5) 10.5 (6–19) P < 0.0005 (LN)
Geometric mean (SD) 27.2 (1.8) 10.6 (2.2)
Length of MV, median (IQR) 19 (14.5–28.5) 6 (3–11) P < 0.0005 (LN)
Geometric mean (SD) 18.8 (1.8) 6.2 (2.3)
